Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBT (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed EBT for 3 consecutive years, with -$3.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBT fell 127.04% year-over-year to -$3.6 million, compared with a TTM value of -$9.7 million through Dec 2024, down 1060.71%, and an annual FY2024 reading of -$13.6 million, down 367.96% over the prior year.
  • EBT was -$3.6 million for Q4 2024 at Oramed Pharmaceuticals, up from -$18.5 million in the prior quarter.
  • Across five years, EBT topped out at $13.3 million in Q4 2023 and bottomed at -$18.5 million in Q3 2024.
  • Average EBT over 3 years is -$4.2 million, with a median of -$4.5 million recorded in 2023.
  • Peak annual rise in EBT hit 385.89% in 2024, while the deepest fall reached 463.61% in 2024.
  • Year by year, EBT stood at -$12.3 million in 2022, then skyrocketed by 207.87% to $13.3 million in 2023, then crashed by 127.04% to -$3.6 million in 2024.
  • Business Quant data shows EBT for ORMP at -$3.6 million in Q4 2024, -$18.5 million in Q3 2024, and $10.8 million in Q2 2024.